These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 22331593

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS, Sharma A, Kumar R, Gupta P, Garg P, Arora SK.
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [Abstract] [Full Text] [Related]

  • 3. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, Moisi D, Mendelson E, Grossman Z, Brenner BG.
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [Abstract] [Full Text] [Related]

  • 4. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A, Paxinos E, Hertogs K, Womac C, Soriano V.
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [Abstract] [Full Text] [Related]

  • 5. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA.
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [Abstract] [Full Text] [Related]

  • 6. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM, Santos AF, Abecasis AB, Van Laethem K, Soares EA, Deforche K, Tanuri A, Camacho R, Vandamme AM, Soares MA.
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [Abstract] [Full Text] [Related]

  • 7. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
    Margerison ES, Maguire M, Pillay D, Cane P, Elston RC.
    J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
    Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, Guimaraes JA, Diaz RS, Antunes OA, Tanuri A.
    J Infect Dis; 2005 Jun 01; 191(11):1961-70. PubMed ID: 15871131
    [Abstract] [Full Text] [Related]

  • 12. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.
    Paolucci S, Baldanti F, Dossena L, Gerna G.
    Antiviral Res; 2006 Mar 01; 69(3):181-5. PubMed ID: 16460817
    [Abstract] [Full Text] [Related]

  • 13. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP.
    J Med Virol; 2008 Dec 01; 80(12):2053-63. PubMed ID: 19040279
    [Abstract] [Full Text] [Related]

  • 14. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
    Asahchop EL, Oliveira M, Brenner BG, Martinez-Cajas JL, Toni Td, Ntemgwa M, Moisi D, Dandache S, Stranix B, Tremblay CL, Wainberg MA.
    Antiviral Res; 2010 Sep 01; 87(3):367-72. PubMed ID: 20541566
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD, Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).
    Antivir Ther; 2006 Sep 01; 11(4):457-63. PubMed ID: 16856619
    [Abstract] [Full Text] [Related]

  • 16. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S, Discotto L, Friborg J, Yang H, Colonno R.
    Antimicrob Agents Chemother; 2005 Sep 01; 49(9):3816-24. PubMed ID: 16127058
    [Abstract] [Full Text] [Related]

  • 17. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
    Holguín A, Suñe C, Hamy F, Soriano V, Klimkait T.
    J Clin Virol; 2006 Aug 01; 36(4):264-71. PubMed ID: 16765636
    [Abstract] [Full Text] [Related]

  • 18. Resistance to protease inhibitors.
    Kuritzkes DR.
    J HIV Ther; 2002 Nov 01; 7(4):87-91. PubMed ID: 12733606
    [Abstract] [Full Text] [Related]

  • 19. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
    Bessong PO.
    Trop Med Int Health; 2008 Feb 01; 13(2):144-51. PubMed ID: 18304259
    [Abstract] [Full Text] [Related]

  • 20. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
    Menzo S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, Baldanti F, Bagnarelli P, Clementi M.
    AIDS; 2003 Mar 28; 17(5):663-71. PubMed ID: 12646788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.